PRTK VS ABSI Stock Comparison

Performance

PRTK
10/100

PRTK returned -12.00% in the last 12 months. Based on SPY's performance of -7.13%, its performance is below average giving it a score of 10 of 100.

ABSI
10/100

ABSI returned -55.13% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

PRTK
93/100

10 analysts offer 12-month price targets for PRTK. Together, they have an average target of 20, the most optimistic target put PRTK at 20 within 12-months and the most pessimistic has PRTK at 20. These analyst ratings are from our partners at Financial Modeling Prep and Alpha Vantage.

ABSI

"Analyst Price Targets" not found for ABSI

Sentiment

PRTK
69/100

PRTK had a bullish sentiment score of 69.17% across Twitter and StockTwits over the last 12 months. It had an average of 8.91 posts, 3.68 comments, and 7.87 likes per day.

ABSI

"Sentiment" not found for ABSI

Technicals

PRTK
86/100

PRTK receives a 85 of 100 based on 14 indicators. 11 are bullish, 1 are bearish.

ABSI
57/100

ABSI receives a 57 of 100 based on 14 indicators. 7 are bullish, 5 are bearish.

Earnings

PRTK
10/100

PRTK has missed earnings 7 times in the last 20 quarters.

ABSI
10/100

ABSI has missed earnings 7 times in the last 20 quarters.

Profit

PRTK
10/100

Out of the last 20 quarters, PRTK has had 1 profitable quarters and has increased their profits year over year on 1 of them.

ABSI
10/100

Out of the last 15 quarters, ABSI has had 0 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

PRTK
49/100

PRTK has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

ABSI
41/100

ABSI has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Paratek Pharmaceuticals, Inc. Summary

Nasdaq / PRTK

Healthcare

Biotechnology

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Absci Corporation Common Stock Summary

Nasdaq / ABSI

Healthcare

Biotechnology

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Power up your portfolio